Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management
OncLive,
Joseph A. Sparano, MD Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality…
Joseph A. Sparano, MD Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality…
Not everyone with breast cancer needs chemotherapy. The treatment recommendations will vary depending on a person’s age, tumor…
Photo credit: © Axel Kock – www.stock.adobe.com A major concern with chemotherapy in premenopausal women is its impact on…
Being treated for breast cancer is taxing enough without receiving more therapy than necessary.
Kevin Kalinsky, MD, MS When a physician-scientist is closely identified with a particular landmark clinical trial, one might…
Jan. 05, 2023 1:25 AM ETEXASFollow Summary According to ARK’s research, Exact Sciences has been a pioneering force in the…
A retrospective analysis of the National Cancer Database suggests an overall survival benefit to adjuvant chemotherapy among…
Long-term recurrence and survival data are now available from the groundbreaking Trial Assigning Individualized Options for…
Long-term recurrence and survival data are now available from the groundbreaking Trial Assigning Individualized Options for…
Long-term recurrence and survival data are now available from the groundbreaking Trial Assigning Individualized Options for…
Pr Mahasti Saghatchian France — L'enthousiasme suscité initialement par les tests génomiques dans le cancer du sein, semble…
This transcript has been edited for clarity. Kathy D. Miller, MD: Welcome to Medscape Oncology Insights.
This transcript has been edited for clarity. Kathy D. Miller, MD: Welcome to Medscape Oncology Insights.
This transcript has been edited for clarity. Lidia Schapira, MD: Hello. I'm Dr Lidia Schapira, and I want to welcome you to…
Findings from a post-hoc analysis identified disparities in Black patients with early hormone receptor–positive breast cancer…
An emerging focus is aligning targeted, safe, and effective therapies with patient goals.
1. For postmenopausal women, invasive disease-free survival and distant relapse-free survival was similar between…
New results from the phase 3 RxPONDER trial add to mounting evidence that most postmenopausal women with early-stage breast…
New results from the phase 3 RxPONDER trial add to mounting evidence that most postmenopausal women with early-stage breast…
When Carmen Brooks was diagnosed with breast cancer late last year, the 56-year-old Bridgeport resident felt the visceral fear…
When Carmen Brooks was diagnosed with breast cancer late last year, the 56-year-old Bridgeport resident felt the visceral fear…
When Carmen Brooks was diagnosed with breast cancer late last year, the 56-year-old Bridgeport resident felt the visceral fear…
When Carmen Brooks was diagnosed with breast cancer late last year, the 56-year-old Bridgeport resident felt the visceral fear…
When Carmen Brooks was diagnosed with breast cancer late last year, the 56-year-old Bridgeport resident felt the visceral fear…
Chemotherapy for breast cancer can help slow the growth of cancer, shrink a tumor, and increase the chance of curing the…
Release Date: April 22, 2020 Expiration Date: April 22, 2021 This activity is provided free of charge.
Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain, according to Ann H.
Introduction Insights from gene expression profiling have vastly expanded our understanding of distinct molecular subtypes of…
This transcript has been edited for clarity. Hi. It's Dr Kathy Miller from Indiana University.
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-p…
オンコタイプDX乳がん再発スコア(TM)検査の臨床現場での役割が明らかに 2020年12月17 日 本件の問い合わせ先 エグザクトサイエンス株式会社 阿部 正美 (03) 4540-7680 [email protected] 本資料はエ…
オンコタイプDX乳がん再発スコア(TM)検査の臨床現場での役割が明らかに 2020年12月17 日 本件の問い合わせ先 エグザクトサイエンス株式会社 阿部 正美 (03) 4540-7680 [email protected]…
2020 年12月17 日 本件の問い合わせ先 株式会社 阿部 正美 (03) 4540-7680 [email protected] 本資料はエグザクトサイエンス米国本社が2020年12月11日に発信したプレスリリースを日本語に翻訳した…
Meeting Coverage > SABCS RSClin incorporates 21-gene recurrence score with tumor grade, size, and more by Contributing Writer…
These data highlight the role of the test in further individualizing treatment decisions in early breast cancer.
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions…
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data…
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:) today announced the presentation of new data at the…
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice - Five-ye…
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions…
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions…
5,000人以上の女性から得られたRxPONDER試験の結果データを発表 2020年12月11日 本件の問い合わせ先 エグザクトサイエンス株式会社 阿部 正美 (03) 4540-7680 [email protected] 本資料はエグ…
5,000人以上の女性から得られたRxPONDER試験の結果データを発表 2020年12月11日 本件の問い合わせ先 エグザクトサイエンス株式会社 阿部 正美 (03) 4540-7680 [email protected]…
2020年12月11日 本件の問い合わせ先 株式会社 阿部 正美 (03) 4540-7680 [email protected] 本資料はエグザクトサイエンス米国本社が2020年12月9日に発信したプレスリリースを日本語に翻訳したもので…
MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data…
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio…
Breast cancer affects 1 in 8 women, a staggering statistic; however, it is a treatable disease with effective screening.
This transcript has been edited for clarity. Kathy D. Miller, MD: Hi. I'm Dr Kathy Miller, professor and associate director of…
This transcript has been edited for clarity. Kathy D. Miller, MD: Hi. I'm Dr Kathy Miller, professor and associate director of…
Laut der TK kann jede Klinik oder Praxis dem Vertrag fr diese spezielle Versorgung beitreten, sofern sie die Teilnahme- und…
Fatima Cardoso, MD Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in…
New data confirm the value of using a 21-gene expression test ( Oncotype DX, Genomic Health) to guide use of adjuvant…
New data confirm the value of using a 21-gene expression test ( Oncotype DX, Genomic Health) to guide use of adjuvant…
New data confirm the value of using a 21-gene expression test ( Oncotype DX, Genomic Health) to guide use of adjuvant…
In women with early-stage breast cancer, positive nodal status alone is probably not justification for administering…
CHICAGO – Clinical risk stratification adds prognostic value to the 21-gene recurrence score for guiding treatment selection in…
Routine use of the Oncotype DX recurrence score to personalize treatment of early breast cancer could reduce the first-year…
在過去,乳癌患者手術治療後,會進行一連串的化療以防止復發,但化療除了患者身體負擔與增加長期額外的健康風險外,費用也是一筆沈重的負擔。根據美國國家癌症研究所(2019)年4月發表的一項研究,診斷為早期乳癌的女性中,若進行基因檢測,可望大幅降低癌症治療的第一年費…
Personalizing treatment for patients with breast cancer based on tumor genetic profiles could reduce costs during the first…
Researchers questioned the legitimacy of clinical trial designs used to gain FDA approval of new oncology drugs based on…
L'importance de différencier les signatures génomiques actuellement disponibles et de personnaliser la chimiothérapie est…
Receive emails about upcoming NOVA programs and related content, as well as featured reporting about current events through a…
Andrew Pecora, MD, FACP, CPE, recently visited Evidence-Based Oncology TM to discuss the progress of COTA’s, a company created…
- Ces résultats renforcent les données déjà nombreuses sur la capacité du test à guider les décisions thérapeutiques et à…
Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the…
Published Results Underscore Value of Oncotype DX® Test in Identifying Women with Early-stage Breast Cancer Who May Receive Life…
PR Newswire REDWOOD CITY, Calif., Nov. 29, 2018 REDWOOD CITY, Calif., Nov. 29, 2018 /PRNewswire/ -- Genomic Health, Inc.
U SVIJETU se posljednjih godina sve brže razvijaju razni genetski testovi koji omogućuju brojne medicinske dijagnostike, odluke…
Aleseia Saunders was overjoyed when she learned that she was pregnant with her first child at age 33.
Mark Robson, MD Determining the optimal adjuvant therapy in young women with breast cancer remains challenging, but some…
Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting Chemotherapy Benefit REDWOOD CITY…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
SOURCE Genomic Health, Inc. Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting…
REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX…
Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting Chemotherapy Benefit PR Newswire…
Die Angst vor der Diagnose Brustkrebs ist groß. Schließlich bekommen mehr als 70.000 Frauen in Deutschland jedes Jahr die…
Tumor ist nicht gleich Tumor: Gentests können bei der Entscheidung helfen, ob eine Chemotherapie bei Brustkrebs nötig ist.